Success Stories: From Cutting-Edge Cancer Genetics to a Green Card: Another EB-2 NIW Success Story

Client’s Testimonial:

“I am extremely grateful for the professional guidance and support I received during my EB-2 NIW application. The Chen Immigration Team helped me clearly present my achievements in cancer genetics and molecular biology, making the process smooth and efficient. Thanks to their expertise, I received my approval on April 10th, 2025 (Processing Time: 10 months, 12 days). I highly recommend their services to other researchers and will refer them to my friends. ”

On April 10^th, 2025, we received another EB-2 NIW (National Interest Waiver) approval for a Research Fellow in the Field of Molecular Biology (Approval Notice).

General Field: Molecular Biology

Position at the Time of Case Filing: Research Fellow

Country of Origin: China

State of Residence at the Time of Filing: Massachusetts

Approval Notice Date: April 10^th, 2025

Processing Time: 10 months, 12 days

Case Summary:

We are honored to support pioneering researchers whose work is not only shaping the future of science but also addressing urgent global health needs. One such client recently secured approval for an EB-2 National Interest Waiver (NIW), marking a major milestone in his journey to continue vital cancer research in the United States.

Tackling Cancer Resistance at the Genetic Level

Our client is a research fellow whose research focuses on uncovering the genetic mechanisms that cause resistance to cancer therapies. By employing state-of-the-art screening techniques, he aims to accelerate the development of next-generation combination therapies that can overcome tumor resistance—an endeavor of both substantial merit and national importance.

This area of research has immense implications. Multidrug resistance is responsible for the majority of cancer treatment failures globally, and this scientist’s work directly addresses this life-threatening problem. From exploring gene targets that affect immunotherapy response to examining the molecular behavior of oncogenic proteins, his work is pushing the boundaries of precision medicine.

A Researcher Positioned for Impact

Currently employed as a research fellow at one of the nation’s leading medical research institutions, the client brings advanced training in biochemistry and molecular biology, along with a prolific academic portfolio. His research has resulted in six peer-reviewed journal articles, one preprint, and one patent application. Several of these publications appear in top-tier journals, including Signal Transduction and Targeted Therapy and the Journal of Hepatology, and are frequently cited in the field.

His work has been cited 369 times, and he has performed peer review for respected journals such as BMC Cancer and Heliyon, with at least 13 completed reviews. At least six of his publications are among the most highly cited in molecular biology and genetics for their publication years—an impressive indicator of the relevance and impact of their work.

Another Approval, Another Step Forward

USCIS approved the client’s EB-2 NIW petition on April 10, 2025, less than a year after filing on May 29, 2024. This success not only affirms the strength of the petition but also underscores the importance of impactful scientific research in immigration pathways.

We are proud to contribute to the success of researchers like this client, whose work carries profound implications for public health and scientific advancement. His story is a testament to what thoughtful strategy, rigorous documentation, and expert advocacy can accomplish.

--------------------------------------------

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With more than 58,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Hundreds and Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our cumulative total of approved cases grew from 600 in 2013 to over 58,000 in 2025.